DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis
Open Access
- 6 December 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 38330
Abstract
The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-γ and TNF. Combination of topical BC-DETC plus intraperitoneal Sbv also significantly reduced disease development and parasite load. The leishmanicidal effect of BC-DETC was extended to human macrophages infected with L. braziliensis, highlighting the feasibility of BC-DETC as a topical formulation for chemotherapy of cutaneous leishmaniasis caused by L. braziliensis.Keywords
This publication has 57 references indexed in Scilit:
- Randomized, Double-Blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in PanamaThe American Journal of Tropical Medicine and Hygiene, 2013
- Cytotoxic T Cells Mediate Pathology and Metastasis in Cutaneous LeishmaniasisPLOS Pathogens, 2013
- Antimicrobial Brazilian Propolis (EPP-AF) Containing Biocellulose Membranes as Promising Biomaterial for Skin Wound HealingEvidence-Based Complementary and Alternative Medicine, 2013
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical diseaseBMC Systems Biology, 2012
- Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future DirectionsMolecular Biology International, 2011
- DETC Induces Leishmania Parasite Killing in Human In Vitro and Murine In Vivo Models: A Promising Therapeutic Alternative in LeishmaniasisPLOS ONE, 2010
- Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled TrialPLOS Neglected Tropical Diseases, 2010
- Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule ScreenPLOS Neglected Tropical Diseases, 2009
- WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled StudyPLOS Neglected Tropical Diseases, 2009